cheap indeed!!!once the report is out and providing its all good, i wouldnt be surprised to see a takeover offer around $1.50.$100m for 23mbbls????hhhmmm
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%